Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company

Analysts at Wells Fargo & Company assumed coverage on shares of Septerna (NASDAQ:SEPN) in a research note issued on Tuesday, MarketBeat reports. The brokerage set an “overweight” rating and a $43.00 price target on the stock. Wells Fargo & Company‘s target price points to a potential upside of 91.11% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. TD Cowen started coverage on Septerna in a report on Tuesday. They issued a “buy” rating for the company. Cantor Fitzgerald assumed coverage on Septerna in a research report on Tuesday. They set an “overweight” rating and a $50.00 price objective on the stock.

Septerna Stock Down 7.0 %

SEPN stock opened at $22.50 on Tuesday. Septerna has a twelve month low of $18.62 and a twelve month high of $26.34.

Insider Activity

In other news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the business’s stock in a transaction on Monday, October 28th. The shares were acquired at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the transaction, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. The trade was a 6.34 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.